We observed that all-trans retinoic acid (ATRA) inhibited the growth of MCF-7 breast cancer cells, but not those transfected with HER2/NEU or its transactivating ligand HEREGULIN. This suggests that Her2/ neu causes breast cancer cells to be resistant to the growth inhibitory effects of ATRA. To confirm this observation, MDA-MB-453 and BT-474 cells, which have high levels of Her2/neu and are resistant to ATRA, were incubated with the trastuzumab (Herceptin TM ) antibody so that we could determine whether inhibition of the expression and function of Her2/neu would resensitize these cells to ATRA. Indeed, we found that MDA-MB-453 and BT-474 cells treated with trastuzumab were growth inhibitory by ATRA. We then determined whether Her2/neu uses Grb2 and Akt proteins to induce ATRA resistance. Liposome-incorporated Grb2 antisense oligonucleotides (L-Grb2) and a dominant negative (DN) AKT mutant were used to down-regulate Grb2 expression and inhibit Akt activity, respectively. When incubated with L-Grb2 or transfected with the DN AKT mutant, ATRA-resistant, Her2/neuoverexpressing cells became sensitive to ATRA. Our results indicate that Her2/neu utilizes Grb2 and Akt proteins to induce ATRA resistance in breast cancer cells. ATRA sensitivity was also correlated with RARa protein levels since higher RARa protein levels were observed in cells in which the Her2/neu pathway was inhibited.
Introduction
All-trans retinoic acid (ATRA) inhibits the growth of various cell types. ATRA mediates its growth inhibitory effects via the retinoic acid receptors (RARs). Upon binding to ATRA, RARs form heterodimers with retinoic X receptors, bind to retinoic acid response elements found in the promoters of target genes, and modulate gene transcription (Mangelsdorf et al., 1994) . Many human breast cancer cell lines are sensitive to the inhibitory actions of ATRA, but there are breast cancer cell lines that are resistant to ATRA (Lotan, 1979; Fraker et al., 1984; Fontana, 1987) . ATRA-resistant breast cancer cell lines are generally negative for the expression of estrogen receptor-a (ERa) and have low levels of RARs, particularly RARa (Sheikh et al., 1994; van der Leede et al., 1995; Fitzgerald et al., 1997; Schneider et al., 2000) .
Amplification of HER2/NEU (also known as ERBB2) is correlated with poor prognosis and survival outcome in patients with breast cancer (Slamon et al., 1987) . This is partly because Her2/neu induces breast cancer cells resistance to chemotherapeutic and biological agents, including tumor necrosis factor-a, tamoxifen, cisplatin, doxorubicin, and paclitaxel (Hudziak et al., 1989; Benz et al., 1992; Pietras et al., 1994; Yu et al., 1996; Baselga et al., 1998) . While comparing the characteristics of ATRA-sensitive and ATRA-resistant breast cancer cell lines, we observed that many ATRA-resistant cell lines, with the exception of SKBr3 cells, have moderate to high expression levels of the Her2/neu protein (Sheikh et al., 1993; Rishi et al., 1996; De Luca et al., 1997) . We hypothesized that Her2/neu induces ATRA resistance in breast cancer cells. Here we report that transfection of HER2/NEU in ATRA-sensitive breast cancer cells caused cells to become ATRA-resistant. Inhibition of Her2/neu by the trastuzumab (Herceptin TM ) antibody sensitized Her2/neu-overexpressing cells to ATRA. Inhibition of the growth factor receptor bound protein-2 (Grb2) and Akt, two well-known downstream signaling proteins of Her2/neu, also sensitized Her2/neu-overexpressing cells to ATRA. Furthermore, we could correlate inhibition of the Her2/neu signaling pathway with increased ATRA sensitivity and increased RARa protein levels.
Results
Her2/neu and heregulin induced ATRA resistance in breast cancer cells
To determine whether Her2/neu could induce ATRA resistance in breast cancer cells, the sensitivity of parental MCF-7 cells to the growth inhibitory effects of ATRA was compared with those of MCF-7 cells transfected with HER2/NEU or HEREGULIN, since Her2/neu is known to be transactivated by heregulin (Lupu et al., 1992; Peles et al., 1992; Plowman et al., 1993; Sliwkowski et al., 1994) . We chose MCF-7 cells because these cells are sensitive to ATRA, have very low levels of Her2/neu (Figure 1a, inset) , and due to their ease of transfection, have been used as a model to study the function of various genes in breast cancer cells . As expected, MCF-7 cells stably transfected with either the HER2/NEU gene (MCF-7/HER2) or the HEREGULIN gene (MCF-7/ HRG) express very high levels of the respective transfected proteins (Figure 1a , inset).
After 5 days of treatment with ATRA, the proliferation of parental MCF-7 cells (MCF-7/WT) was inhibited in a dose-dependent manner (Figure 1a) . At 1 mM concentration, ATRA inhibited MCF-7/WT cell growth by 63%. The sensitivity of vectortransfected cells (MCF-7/V) to ATRA was similar to that of MCF-7/WT cells (data not shown). However, ATRA did not inhibit the proliferation of MCF-7/ HER2 or MCF-7/HRG cells ( Figure 1a ). This is despite the fact that the expression levels of ERa are similar among MCF-7/WT, MCF-7/HER2 and MCF-7/HRG cells (Figure 1a, inset) .
Since Her2/neu and EGFR are related family members, we determined whether EGFR could also induce ATRA resistance. The levels of EGFR in MCF-7 cells transfected with vector control (MCF-7/V) are almost undetectable, whereas the levels of EGFR in MCF-7 cells stably transfected with the EGFR gene (MCF-7/EGFR cells) are very high (Figure 1b, inset) . The expression levels of ERa in both cell lines are quite similar (Figure 1b, inset) . At 1 mM concentration, ATRA inhibited the growth of MCF-7/V cells by approximately 51% (Figure 1b ). In the presence or absence of EGF, ATRA inhibited the growth of MCF-7/EGFR cells to a very similar extent, approximately 39 -43% (Figure 1b) .
To avoid the bias of using only one clone of MCF-7/ HER2 and one clone of MCF-7/HRG cells, we decided to determine whether heregulin, when added exogenously, could also reduce the sensitivity of MCF-7 cells to ATRA. When MCF-7 cells were incubated with 10 nM concentration of ATRA in phenol red-free DMEM/F12 medium+10% CSS, the growth of MCF-7 cells was reduced by 56%, whereas in the presence of 100 ng/ml heregulin, the same dose of ATRA reduced MCF-7 cell growth by 20% (Figure 2 ; P=0.006). This reduced sensitivity of MCF-7 cells to ATRA by heregulin was observed when cells were incubated with up to 250 nM ATRA (Figure 2 ). However, heregulin did not affect the sensitivity of MCF-7 cells to ATRA when the cells were incubated with higher doses of ATRA. At 1 mM concentration, ATRA reduced the growth of MCF-7 cells by 71% in the absence of heregulin, and 55% in the presence of heregulin (P40.05). Thus, in the presence of heregulin, MCF-7 cells became less sensitive to low doses of ATRA. Heregulin also reduced the sensitivity of another breast cancer cell line, T-47D, to ATRA (data not shown). These data indicate that overexpression or activation of Her2/neu led to ATRA resistance in breast cancer cells.
Reduced RARa protein levels were found in MCF-7 cells transfected with Her2/neu or heregulin Since the sensitivity of breast cancer cells to ATRA has been correlated with RARa expression (Sheikh et al., 1994; van der Leede et al., 1995; Fitzgerald et al., 1997; Schneider et al., 2000) , we examined the expression of RARs in MCF-7 parental cells and its variants. 3 cells/well in 96-well plates in phenol red-free DMEM/F12 medium+10% CSS (in the presence or absence of 5 ng/ml EGF). All cell lines were incubated with increasing doses of ATRA (0 -1000 nM) for 5 days. Cell growth was determined by the CellTiter 96 AQueous nonradioactive proliferation assay. Growth of treated cells was compared with that of untreated cells; results are expressed as percentage of untreated cells. Each data point represents an average of triplicate wells+stan-dard deviation. Insets, (a) Western blot was used to determine the expression levels of HER2/neu, heregulin, and ERa in MCF-7/ WT, MCF-7/HER2, and MCF-7/HRG cells; (b) Western blot was used to determine the expression levels of EGFR and ERa in MCF-7/V and MCF-7/EGFR cells
Inhibition of Grb2 and Akt proteins induced ATRA sensitivity in Her2/neu-overexpressing cells
We have previously demonstrated that Grb2 protein is vital to the proliferation of breast cancer cells that have high expression levels of Her2/neu or heregulin (Tari et al., 1999; Lim et al., 2000) , so we examined whether Grb2 protein may also be vital to ATRA sensitivity.
Liposomal Grb2 antisense oligos (L-Grb2), but not liposomal control oligos (L-control), decreased Grb2 protein expression (Figure 5a ). When MDA-MB-453 cells were incubated with 6 mM L-Grb2 alone, growth inhibition was 32%. However, when MDA-MB-453 cells were preincubated with L-Grb2 before being incubated with 1 mM ATRA, growth inhibition was increased to 52% (Figure 5b ; P=0.018). The increased ATRA sensitivity was specific, because Lcontrol did not modulate the sensitivity of MDA-MB-453 cells to ATRA (Figure 5b ). When MCF-7/HER2 cells were incubated with 12 mM L-Grb2 alone, growth inhibition was 30% (Figure 5c ). But when MCF-7/ HER2 cells were incubated with L-Grb2 and 1 mM ATRA, growth inhibition of MCF-7/HER2 cells was increased to 53% (Figure 5c ; P=0.037). L-control also did not increase the sensitivity of MCF-7/HER2 cells to ATRA (Figure 5c ). Similarly, L-Grb2, but not Lcontrol, increased the sensitivity of MCF-7/HRG cells to ATRA (data not shown). However, both L-Grb2 and L-control failed to modulate the sensitivity of MCF-7/WT cells to ATRA (Figure 5d ). These data indicate that Grb2 is used by Her2/neu-overexpressing breast cancer to regulate ATRA sensitivity.
We have earlier shown that Grb2 protein regulates Akt activity in breast cancer cells that have high levels of Her2/neu or heregulin (Lim et al., 2000) . Since down-regulation of Grb2 protein sensitized Her2/neuoverexpressing breast cancer cells to ATRA, inhibition of Akt activity might also sensitize breast cancer cells to ATRA. We compared the ATRA sensitivity of MDA-MB-453 parental cells to those stably transfected with the dominant negative AKT mutant (MDA-MB-453/DN Akt) . As shown previously, parental MDA-MB-453 cells were resistant to ATRA ( Figure 6a) ; however, MDA-MB-453/DN Akt cells were sensitive to ATRA. At 1 mM concentration, ATRA induced 42% growth inhibition in MDA-MB-453/DN Akt cells (Figure 6a; P50.001 ). These data demonstrate that Akt is vital for Her2/neu to induce ATRA resistance in breast cancer cells. Moreover, compared with parental cells, MDA-MB-453/DN Akt cells had higher endogenous RARa expression levels ( Figure 6b ).
Discussion
Our data indicate that Her2/neu, when overexpressed or activated, induces ATRA resistance in breast cancer cells. Her2/neu is known to induce tumor resistance to various chemotherapeutic and biological agents. However, little is known about the role of Her2/neu in regulating breast cancer resistance to ATRA. We showed that transfection of HER2/NEU or its Figure 2 Heregulin reduced the sensitivity of MCF-7 cells to ATRA. MCF-7 cells were plated at 1.5610 3 cells/well in 96-well plates in DMEM/F12 medium+5% FBS. After overnight adherence, the medium was changed to phenol red-free DMEM/F12 medium+10% CSS. MCF-7 cells were treated with increasing doses of ATRA (0 -1000 nM) in the presence or absence of heregulin (100 ng/ml). After 5 days, cell growth was determined. The growth of treated cells was compared with that of untreated cells cultured under the same conditions; results are expressed as percentage of untreated cells. Each data point represents an average of triplicate wells+standard deviation. t-test (at 95% confidence) was used to determine the statistical significance of the cells treated with the same doses of ATRA in the absence and the presence of heregulin (*P50.05) Figure 3 Lower levels of RARa protein were found in MCF-7 cells transfected with Her2/neu or heregulin. Protein lysates were obtained from untreated exponentially growing cells. Western blots were performed to determine the expression of RARa, RARb, RARg proteins. Densitometric scans were performed on Western blots to measure the ratio of RARa to b-actin. The percentage of RARa expression was calculated as (ratio of RARa to b-actin in transfected cells/ratio of RARa to b-actin in parental cells)6100. MCF-7/ADR cells were used as a negative control for RARa expression and Hs578T cells were used as a positive control for RARb expression activating ligand HEREGULIN induces ATRA resistance. We further demonstrated, in a different system such as one that overexpresses Her2/neu, that when Her2/neu is blocked by trastuzumab, breast cancer cells became sensitive to ATRA. It has been shown that expression and activation of RARa alone are sufficient for retinoids-mediated responses (Schneider et al., 2000) . We found that ATRA sensitivity was correlated with RARa expression levels. When breast cancer cells are resistant to ATRA, they have low levels of RARa protein. But when the cells became sensitive to ATRA, such as by using trastuzumab, the RARa protein levels were increased.
The main mechanism by which ATRA inhibits the proliferation of breast cancer cells is by inducing G1 cell cycle arrest (Wilcken et al., 1996; Toma et al., 1997 Toma et al., , 1998 Mangiarotti et al., 1998) . Breast cancer cells became growth arrested when they were incubated with ATRA for 3 or more days. ATRA may induce apoptosis in breast cancer cells but only when the cells have been continuously exposed to ATRA for 6 or more days, with continuous replenishment of ATRA in the medium every other day. The ATRA-mediated G1 arrest of the cell cycle is a coordinated event that requires the ubiquitylation and degradation of two proteins: Skp2, an F-box Kip1 for degradation, and cyclin D1 (Dow et al., 2001) . Coincidentally, overexpression and/or activation of Her2/neu lead to deregulation of p27 Kip1 and cyclin D1 stability (Yang et al., 2000; Lenferink et al., 2001) , which are reversible by the trastuzumab antibody. Thus, Her2/ neu may induce ATRA resistance in breast cancer cells by suppressing RARa expression, and/or dereg- ulating the transition of G1 to S phase of the cell cycle. Transfection of c-jun into breast cancer cells increased AP-1 transcriptional activity and ATRA resistance (Yang et al., 1997) . Higher basal AP-1 activity has been reported in cells that have constitutive activation of Her2/neu (Galang et al., 1996) . Her2/neu may also induce ATRA resistance by increasing AP-1 transcriptional activity.
Both Grb2 and Akt proteins are vital for Her2/neu signaling. Upon activation, Her2/neu becomes tyrosine phosphorylated and binds to Grb2 (Meyers et al., 1994) . Grb2 then links Her2/neu to the activation of multiple downstream signaling pathways. Although overexpression of Grb2 itself does not lead to cellular transformation (Lowenstein et al., 1992) , Grb2 is crucial for transformation and proliferation induced by various tyrosine kinases, including that of Her2/neu (Xie et al., 1995) . However, Grb2 has not been implicated in the modulation of ATRA or chemotherapy sensitivity.
We have shown that Grb2 regulates Akt activity in heregulin-stimulated and Her2/neu overexpressing breast cancer cells (Lim et al., 2000) . Increased Akt activity has been found in many types of cancer. Activation of Akt could be due to AKT gene amplification (Bellacosa et al., 1995) , inactivating mutations of its suppressor PTEN (Steck et al., 1997) , or stimulation by growth factors and their receptors (Alessi et al., 1996; Burgering and Coffer, 1995; Franke et al., 1995) . Regardless of the activation mechanism, increased Akt activity can enhance proliferation and prolong cell survival. Akt has been found to modulate the activities of multiple proteins but has not been found to regulate RARa expression. We are currently investigating whether the regulation of RARa expression is mediated directly by Akt or by proteins downstream of Akt and whether RARa regulation is at the transcriptional or translational level.
ATRA resistance had been found in breast cancer cell lines that have high levels of EGFR; however, we did not find EGFR to be directly involved in inducing ATRA resistance in breast cancer cells. With the exception of glioblastomas (Hoi Sang et al., 1995) , our findings agree with those of numerous reports, documenting that ATRA suppresses EGFR-associated cell proliferation by decreasing EGFR tyrosine phosphorylation, EGFR levels, as well as EGFR downstream signals, Erk1,2 (Roulier et al., 1994; Muller et al., 1997; Carter and Shaw, 2000; Sah et al., 2002) .
The signaling pathways and the biological effects induced by EGFR and Her2/neu are not always identical, despite the fact that these two receptor tyrosine kinases are highly homologous. We found that serum growth factors and Grb2 predominantly regulate Akt activity in Her2/neu-overexpressing cells, while serum growth factors and Grb2 predominantly regulate Erk1,2 activities in EGFR-overexpressing cells Lim et al., 2000) . Other groups illustrated that it was the expression/ activation of Her2/neu, not EGFR, which promotes the retention of Raf-1 in the plasma membrane (Zhang et al., 2002) , reinitiates the proliferation of growth-arrested mammary epithelial acini, and induces the luminal repopulation of mammary epithelial acini (Muthuswamy et al., 2001) . Furthermore, Her2/neu and EGFR can preferentially bind to different signaling proteins; the Csk-homologous kinase binds exclusively to Her2/neu (Zrihan-Licht et al., 1997) , whereas the Cbl protein binds exclusively to EGFR (Levkowitz et al., 1996; Muthuswamy et al., 1999) . In that context, Her2/neu, not EGFR, induces ATRA resistance in breast cancer cells. Amplification of the HER2/NEU gene has been correlated with poor prognosis in patients with breast cancer (Slamon et al., 1987) . Thus therapeutic strategies that aim to inhibit Her2/neu, such as the trastuzumab antibody, and the tumor-suppressor genes E1A and PEA-3 (Yu et al., 1992; Xing et al., 2000) , have been developed to treat such breast cancer patients. The therapeutic potential of these agents might be improved by combining with chemotherapeutic drugs. Here we identify a novel alternative therapeutic strategy against Her2/neu-overexpressing breast tumors: combining the biological agent ATRA with inhibition of the Her2/neu-Grb2-Akt pathway.
Materials and methods

Cell lines
MCF-7, T-47D, MDA-MB-453, BT-474, and Hs578T cells were obtained from American Type Cell Culture (Manassas, VA, USA). MCF-7 cells transfected with the HEREGULIN b-2 gene (MCF-7/HRG), the HER2/NEU gene (MCF-7/ HER2), and the EGFR gene (MCF-7/EGFR) were kindly provided by Dr Ruth Lupu (Berkeley, CA, USA), Dr MienChie Hung (Houston, TX, USA) and Dr Francis G Kern (Birmingham, AL, USA), respectively. These cells were originally termed as MCF-7/T7 (Tang et al., 1996) , MCF-7/HER2-18 (Benz et al., 1992) , and MCE5 . Cells were cultured in Dulbecco's modified Eagles's medium (DMEM)/F12 medium supplemented with 5% heatinactivated fetal bovine serum (FBS). MCF-7/EGFR cells were cultured in phenol red-free DMEM/F12 medium supplemented with 10% charcoal-stripped fetal bovine serum (CSS). MDA-MB-453 cells stably transfected with the HAtagged cDNA encoding the dominant negative AKT mutant (K179M) were provided by Dr Mien-Chie Hung and has been previously described . MCF-7/ADR cells were provided by Dr Kapil Mehta (Houston, TX, USA).
Antibodies and ligands
Monoclonal antibodies specific for Her2/neu and Estrogen Receptor-a (ERa) were purchased from Oncogene Research Products (Boston, MA, USA) and Novocastra Laboratories Ltd. (Burlingame, CA, USA), respectively. Antibodies specific for EGFR and heregulin were obtained from NeoMarkers (Fremont, CA, USA). Polyclonal RARa, RARb, and RARg antibodies were purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA). b-Actin and Grb2 antibodies were purchased from Sigma Chemical Co. (St. Louis, MO, USA) and BD Transduction Laboratories (San Diego, CA, USA), respectively. Anti-mouse and anti-rabbit secondary antibodies were obtained from Amersham Life Sciences (Cleveland, OH, USA). ATRA was obtained from Sigma Chemical Co. Heregulin b1 was purchased from NeoMarkers. Trastuzumab (Herceptin TM ) was kindly provided by Genentech (San Francisco, CA, USA).
Liposomal oligodeoxynucleotides (oligos)
Nuclease resistant P-ethoxy oligos (18 bases) were purchased from Oligos Etc., Inc. (Wilsonville, OR, USA). We have previously reported the sequences of the Grb2 antisense and the control oligos (Tari et al., 1999; Lim et al., 2000) as follows: Grb2 antisense, 5'-ATATTTGGCGATGGCTTC-3'; control oligo, 5'-GGGCTTTTGAACTCTGCT-3'. Grb2 antisense and control oligos were mixed with dioleoylphosphocholine (Avanti Polar Lipids, Alabaster, AL, USA) in the presence of tertiary butanol and prepared as described (Tari et al., 1999; Lim et al., 2000) .
Cell growth and viability assay
Breast cancer cells were seeded in 96-well plates in 0.1 ml of DMEM/F12 medium supplemented with 5% FBS. The next day, ATRA was added to the cells. When the sensitivity to ATRA was studied in MCF-7/EGFR cells, the culture medium was changed to phenol red-free DMEM/F12 supplemented with 10% CSS before adding ATRA. This medium is necessary to maintain high expression of EGFR in transfected cells . After 5 days of incubation, cell growth was measured by using the CellTiter 96 AQueous nonradioactive proliferation assay (Promega, Madison, WI, USA).
Western blots
Cell lysates were obtained from untreated exponentially growing cells or from cells treated with trastuzumab. Proteins were electrophoresed and electrotransferred as previously described (Lim et al., 2000) . Membranes were incubated with the appropriate primary and secondary antibodies. Protein bands were visualized by enhanced chemiluminescence (Kirkegaard and Perry Laboratories, Gaithersburg, MD, USA). Images were scanned and quantified by using an Alpha Innotech densitometer using the Alpha Imager application program (Alpha Innotech, San Leandro, CA, USA).
Statistical analysis
Statistical analysis was performed using StatView 5.0 (SAS Institute, Cary, NC, USA). The differences between individual treatments of cells were analysed using two-tailed paired t-test.
